J Petimar1, É O'Reilly1,2, H-O Adami3, P A van den Brandt4, J Buring5, D R English6,7, D M Freedman8, G G Giles6,7, N Håkansson3, T Kurth9, S C Larsson3, K Robien10, L J Schouten4, E Weiderpass3,11, A Wolk3, S A Smith-Warner1. 1. Harvard T.H. Chan School of Public Health, Boston, MA, USA. 2. School of Public Health, College of Medicine, University College Cork, Cork, Ireland. 3. Karolinska Institutet, Stockholm, Sweden. 4. Caphri School, Maastricht University, Maastricht, The Netherlands. 5. Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 6. Cancer Council Victoria, Melbourne, VIC, Australia. 7. Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia. 8. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 9. Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany. 10. Milken Institute School of Public Health, The George Washington University, Washington, DC, USA. 11. Institute of Population-Based Cancer Research, Oslo, Norway.
Abstract
BACKGROUND AND PURPOSE: Caffeine is associated with a lower risk of some neurological diseases, but few prospective studies have investigated caffeine intake and risk of amyotrophic lateral sclerosis (ALS) mortality. We therefore determined associations between coffee, tea and caffeine intake, and risk of ALS mortality. METHODS: We conducted pooled analyses of eight international, prospective cohort studies, including 351 565 individuals (120 688 men and 230 877 women). We assessed coffee, tea and caffeine intake using validated food-frequency questionnaires administered at baseline. We used Cox regression to estimate study- and sex-specific risk ratios and 95% confidence intervals (CI) for ALS mortality, which were then pooled using a random-effects model. We conducted analyses using cohort-specific tertiles, absolute common cut-points and continuous measures of all exposures. RESULTS: During follow-up, 545 ALS deaths were documented. We did not observe statistically significant associations between coffee, tea or caffeine intake and risk of ALS mortality. The pooled multivariable risk ratio (MVRR) for ≥3 cups per day vs. >0 to <1 cup per day was 1.04 (95% CI, 0.74-1.47) for coffee and 1.17 (95% CI, 0.77-1.79) for tea. The pooled MVRR comparing the highest with the lowest tertile of caffeine intake (mg/day) was 0.99 (95% CI, 0.80-1.23). No statistically significant results were observed when exposures were modeled as tertiles or continuously. CONCLUSIONS: Our results do not support associations between coffee, tea or total caffeine intake and risk of ALS mortality.
BACKGROUND AND PURPOSE:Caffeine is associated with a lower risk of some neurological diseases, but few prospective studies have investigated caffeine intake and risk of amyotrophic lateral sclerosis (ALS) mortality. We therefore determined associations between coffee, tea and caffeine intake, and risk of ALSmortality. METHODS: We conducted pooled analyses of eight international, prospective cohort studies, including 351 565 individuals (120 688 men and 230 877 women). We assessed coffee, tea and caffeine intake using validated food-frequency questionnaires administered at baseline. We used Cox regression to estimate study- and sex-specific risk ratios and 95% confidence intervals (CI) for ALSmortality, which were then pooled using a random-effects model. We conducted analyses using cohort-specific tertiles, absolute common cut-points and continuous measures of all exposures. RESULTS: During follow-up, 545 ALS deaths were documented. We did not observe statistically significant associations between coffee, tea or caffeine intake and risk of ALSmortality. The pooled multivariable risk ratio (MVRR) for ≥3 cups per day vs. >0 to <1 cup per day was 1.04 (95% CI, 0.74-1.47) for coffee and 1.17 (95% CI, 0.77-1.79) for tea. The pooled MVRR comparing the highest with the lowest tertile of caffeine intake (mg/day) was 0.99 (95% CI, 0.80-1.23). No statistically significant results were observed when exposures were modeled as tertiles or continuously. CONCLUSIONS: Our results do not support associations between coffee, tea or total caffeine intake and risk of ALSmortality.
Authors: Stephanie A Smith-Warner; Donna Spiegelman; John Ritz; Demetrius Albanes; W Lawrence Beeson; Leslie Bernstein; Franco Berrino; Piet A van den Brandt; Julie E Buring; Eunyoung Cho; Graham A Colditz; Aaron R Folsom; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Lisa Harnack; Pamela L Horn-Ross; Vittorio Krogh; Michael F Leitzmann; Marjorie L McCullough; Anthony B Miller; Carmen Rodriguez; Thomas E Rohan; Arthur Schatzkin; Roy Shore; Mikko Virtanen; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; David J Hunter Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: A R Folsom; L H Kushi; K E Anderson; P J Mink; J E Olson; C P Hong; T A Sellers; D Lazovich; R J Prineas Journal: Arch Intern Med Date: 2000-07-24
Authors: Mia Hashibe; Carlotta Galeone; Saundra S Buys; Lisa Gren; Paolo Boffetta; Zuo-Feng Zhang; Carlo La Vecchia Journal: Br J Cancer Date: 2015-08-20 Impact factor: 7.640
Authors: Mark Obrenovich; Hayden Jaworski; Tara Tadimalla; Adil Mistry; Lorraine Sykes; George Perry; Robert A Bonomo Journal: Microorganisms Date: 2020-05-23
Authors: Hatice Tankisi; Christina S-Z Nielsen; James Howells; Bülent Cengiz; Gintaute Samusyte; Martin Koltzenburg; Jakob U Blicher; Anette T Møller; Kirsten Pugdahl; Anders Fuglsang-Frederiksen; Mamede de Carvalho; Hugh Bostock Journal: Eur J Neurol Date: 2021-07-22 Impact factor: 6.288